All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

June 16th 2025

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

June 16th 2025

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

FDA Grants Orphan Drug Designation to CID-078 for SCLC

June 16th 2025

The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.

Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma

June 16th 2025

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

Using Self-Directed Learning to Combat Information Overload in Oncology Fellowship

June 16th 2025

Jill Gilbert, MD, discusses how principles of adult learning theory can be applied to hematology/oncology fellowship.

QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation

June 16th 2025

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

June 15th 2025

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL

June 15th 2025

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL

June 15th 2025

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.

BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL

June 15th 2025

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

Five Under 5: Top Oncology Videos for the Week of 6/8

June 15th 2025

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression

June 15th 2025

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

June 14th 2025

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma

June 14th 2025

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML

June 14th 2025

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.

Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma

June 14th 2025

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.